Dr. Sean Matthew McBride, MD

Dr. McBride practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. McBride's NPI, 1265671879, was assigned on February 5, 2009. Dr. McBride graduated from Yale School of Medicine in 2008. Dr. McBride holds New York license 269129.

Dr. McBride's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. McBride's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Monmouth. Dmand AI also links Dr. McBride to 4 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McBride practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. McBride's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. McBride is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. McBride's licenses on file in 4 states: New York, Florida, New Jersey and Massachusetts.

Dmand AI lists bladder cancer radiation, bone cancer radiation, head & neck cancer radiation and prostate cancer radiation among the conditions Dr. McBride treats.

CMS data shows 2,939 Medicare services from Dr. McBride across 13 procedure codes in 2024, for 346 Medicare patients. Medicare paid $224,764 for them.

CMS counts 346 Medicare patients who saw Dr. McBride in 2024. The largest group is 65 to 74, with 178 patients. 75% of them have cancer, and 75% have high cholesterol. 10% are also on Medicaid. Their average risk score is 1.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McBride's median patient age at 73, with 6% women.

In 2024, Dr. McBride wrote 144 Medicare Part D claims for 57 patients. 66% of them were for generic drugs. CMS names the drug for 58 of them, across 2 drugs with 11 or more claims each, at $77,426 in total drug cost. In 2023, CMS named 21 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. McBride for performance year 2024, reported as part of a group. Dr. McBride accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. McBride as offering telehealth.

Dmand AI links 56 papers to Dr. McBride, published from 2011 to 2025. 2022 was the busiest year, with 12. The most frequent topics are Prostatic Neoplasms, Head and Neck Neoplasms and Radiotherapy Dosage. Dr. McBride has published most often in J Urol. Dr. McBride's most frequent co-authors are Nancy Lee, MD, Nadeem Riaz, MD and Marisa A. Kollmeier, MD.

Dmand AI links Dr. McBride to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 38 general payments to Dr. McBride from 8 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Bristol-Myers Squibb Company paid the most, $14,325.

Dr. McBride graduated from Yale School of Medicine in 2008.

Dr. McBride is in network with 13 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.